Allos Continues to Outperform - Analyst Blog
25 Novembro 2011 - 10:15AM
Zacks
We are maintaining our Outperform
recommendation on Allos Therapeutics Inc. (ALTH)
following the announcement of decent third quarter 2011 results by
the company.
Allos Therapeutics, a Westminster,
Colorado based biopharmaceutical company, announced its third
quarter 2011 results in November 2011. The company suffered a
loss of $0.11 per share in the quarter, narrower than the year-ago
loss of $0.18 and the Zacks Consensus loss estimate of $0.15.
The narrower loss was primarily
attributable to higher revenues recorded in the third quarter of
2011. The higher revenues were driven by increased sales of Allos’
sole marketed product, Folotyn. The drug is marketed for the
treatment of patients with relapsed or refractory peripheral T-cell
lymphoma.
Apart from the earnings report,
Allos terminated the proposed merger with AMAG
Pharma (AMAG) in October 2011. The deal was called off as
it failed to garner shareholder support. We view this development
as a positive for Allos, as the merger did not have enough
strategic rationale behind it.
The sole marketed products of AMAG
and Allos, Feraheme and Folotyn, respectively, have been performing
below expectations and do not indicate that sales would improve
following the merger. With the deal coming to an end, we believe
Allos will be able to focus its attention on making Folotyn a
success.
We continue to believe that Allos’
shares are undervalued at current levels with significant scope for
upside. In our view, the current price represents an attractive
entry point for long-term investors.
ALLOS THERAPEUT (ALTH): Free Stock Analysis Report
AMAG PHARMA INC (AMAG): Free Stock Analysis Report
Zacks Investment Research
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024
Notícias em tempo-real sobre Allos Therapeutics, Inc. (MM) da NASDAQ bolsa de valores: 0 artigos recentes
Mais Notícias de Allos Therapeutics, Inc. (MM)